levetiracetam

FDA Drug Profile — Levetiracetam, Spritam, levetiracetam, Keppra XR, Keppra

levetiracetam is listed in the FDA National Drug Code directory with 56 NDC codes, marketed under brand names including Levetiracetam, Spritam, levetiracetam. Available dosage forms: tablet, for suspension, tablet, film coated, injection, injection, solution, concentrate, tablet, film coated, extended release.

Drug details

Generic Name
levetiracetam
Brand Names
Levetiracetam, Spritam, levetiracetam, Keppra XR, Keppra, Levetiracetam Extended-Release, ELEPSIA XR 1000 MG, LEVETIRACETAM, ELEPSIA XR 1500 MG
Application Number
NDA207958
Sponsor
Prasco Laboratories
NDC Codes
56
Dosage Forms
TABLET, FOR SUSPENSION, TABLET, FILM COATED, INJECTION, INJECTION, SOLUTION, CONCENTRATE, TABLET, FILM COATED, EXTENDED RELEASE, INJECTION, SOLUTION, POWDER, TABLET, EXTENDED RELEASE, SOLUTION
Routes
ORAL, INTRAVENOUS
Active Ingredients
LEVETIRACETAM

Indications and Usage

1 INDICATIONS AND USAGE Levetiracetam is indicated for the treatment of partial-onset seizures in patients 1 month of age and older (1.1) Levetiracetam is indicated for adjunctive therapy for the treatment of: • Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy (1.2) • Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy (1.3) 1.1 Partial-Onset Seizures Levetiracetam tablets are indicated for the treatment of partial-onset seizures in patients 1 month of age and older. 1.2 Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy Levetiracetam tablets are indicated as adjunctive therapy for the treatment of myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy. 1.3 Primary Generalized Tonic-Clonic Seizures Levetiracetam tablets are indicated as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.